Tag John Kraus

New Treatments, News

FDA clears Rejoyn™, the first prescription digital therapeutic authorized for the adjunctive treatment of MDD symptoms

Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn™ (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms…

April 1, 2024

Clinical Trials, News

Otsuka announced positive results of Phase 3 clinical trials of centanafadine for the treatment of adolescents and children with ADHD.

Otsuka Pharmaceutical Companies (U.S.) and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and…

October 27, 2023